INDIA PESTICIDES LTD · QQ1 FY-2027 · THE CALL

Q1 slump overshoots guidance; long-term capex intact but near-term stalled

The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.

Q1 FY27 results IPLIndia Pesticides Ltd18 Aug 2026 · 6 min read

Verdict

Hold

confidence 6/10

Credibility

Grade B

Hit one-offs (₹2.5 Cr write-off + ₹6 Cr job work); FY27 guidance cut from 20% to single-digit growth.

Short-term outlook

Cautiously Optimistic

next 1–2 quarters

Long-term outlook

Optimistic

multi-year

Q1 revenue missed at -9.2% YoY (vs prior ≥20% FY27 guidance) and PAT crashed -34.8%, driven by monsoon-driven Pretilachlor volume collapse (-13%) and cost inflation. Management disclosed ₹8.5 Cr one-time charges, and inventory built speculatively now needs normalization. Long-term capex roadmap (Hamirpur ₹1,000 Cr, EU approval +₹30-40 Cr) remains credible but execution is 2-3 years out. Risk: sustained monsoon volatility or Hamirpur ramp delay could extend near-term pain.

₹256 Cr

Revenue · −9.2% YoY

₹23 Cr

Reported PAT · −34.3% YoY

Compressing

Margins · vs guidance: Overstated

Did the claims hold up?

Management's claims vs. the numbers

Softer domestic demand, Pretilachlor hit by erratic rains

MET

Volume -13%, price +4%; domestic revenue ₹167 Cr vs ₹195 Cr YoY

One-time charges ₹8.5 Cr (₹2.5 Cr write-off + ₹6 Cr job work) impaired Q1 EBITDA

MET

EBITDA 15.4%, without one-offs would be ~18.5%; breakdown confirmed in Q&A

FY27 will achieve lower single-digit growth

MISS

Q1 at -9.2%; prior call guided ≥20% FY27. Downgrade from 20% to <10%.

Hamirpur FY27 revenue ₹50-60 Cr from 2 new blocks

OVERSTATED

Prior implied ₹70-100 Cr; revised down. Not yet delivered; forward claim.

EU TEQ approval allows ₹30-40 Cr additional revenue from Nov 2026

Unverified

Approval real, sales from Nov when customers add as source. Credible but forward.

Earnings quality

What changed since the last call

Deltas vs. the prior call

FY27 growth guidance slashed

Downgrade

Prior FY27 ≥20% growth; CFO now says 'lower single-digit growth.' Q1 at -9.2% makes recovery steep.

Hamirpur FY27 capex output cut

Downgrade

Implied ₹70-100 Cr FY27 from Hamirpur; revised to ₹50-60 Cr. Only 2/10 blocks online; ramp slower than prior expectations.

EBITDA margin target moderated

Downgrade

Prior 18-20% guidance; Q1 delivered 15.4%. Management now targets 15-18% sustainable, below prior band.

Margin pressure narrative confirmed

Neutral

One-offs (₹8.5 Cr) + higher fuel/labor costs + volume loss all cited. Normalized margin ~18%, not 20%+.

Product diversification initiated

New

3 new molecules in FY27 (fungicide already started, new herbicide at Sandila, herbicide MMP at Hamirpur). Reduces Pretilachlor dependence.

The Q&A

Analysts pressed hard on margin collapse (Yogansh), capex vs. guidance alignment (Kaushal), and Pretilachlor concentration (Karan). Management held, explaining one-offs and pivoting to long-term strategy. No evasions; tone cautious, not defensive. Score 7/10.

The exchanges that mattered

Margin collapse drivers — Yogansh Jeswani, Mittal Analytics

Answered

₹2.5 Cr export receivable write-off + ₹6 Cr higher job work charges for herbicide intermediates. Fuel cost also up.

Volume vs. pricing split — Karan Shah, GeeCee

Answered

Volume -13%, price +4%. Demand hit by erratic rains.

Product concentration risk — Karan Shah, GeeCee

Partial

Adding 3 molecules in FY27 to diversify. Reduces dependence on any single product.

Hamirpur capex roadmap — Kaushal Sharma, Equinox

Answered

8-10 blocks total; 2 blocks operational now, 1 more this year, 1 under construction. ₹100 Cr annual capex, 3-4 years to ₹1,000 Cr.

EU TEQ approval monetization — Saket Kapoor, Kapoor Co

Answered

Prior ₹100 Cr annual sales; TEQ allows direct selling, adds ₹30-40 Cr. Sales from Nov; 1-2 months for customer approval.

New fungicide product viability — Yogansh Jeswani, Mittal Analytics

Answered

India imports 4k-5k MT/yr; IPL targets 2k MT. Price ₹500-600/kg (₹10-12 Cr revenue). Capex ₹2-3 Cr for existing block balancing.

FY27 growth guidance — Karan Shah, GeeCee

Partial

Expecting Q3/Q4 better, so lower single-digit growth this year.

Shalvis (subsidiary) contribution — Vidhi Shah, CR Kothari

Answered

₹3 Cr, but netted off internally since RM purchased from IPL. ₹50-60 Cr expected FY27 from 2 blocks.

Capacity utilization — Kaushal Sharma, Equinox

Answered

70%. Headroom for growth.

Receivables and working capital — Kaushal Sharma, Equinox

Answered

Receivables stable at 120 days. Inventory up from 170 to 200 days due to lower Q1 sales; will normalize to 170 in Q3.

Guidance

Forward guidance and management's confidence

FY27 lower single-digit growth (revised down from ≥20%)

Medium

Q1 -9.2%; recovery depends on Q3/Q4 monsoon recovery. Capex ramp and new products not yet material.

Hamirpur FY27 ₹50-60 Cr revenue

Medium

2 blocks operational/starting this year. Downward revision from prior ₹70-100 Cr hope. Not yet delivered.

EU approval ₹30-40 Cr incremental from Nov 2026

Medium

Real approval; prior base ₹100 Cr. Ramp depends on customer approvals (1-2 months estimated).

EBITDA margin 15-18% sustainable (revised from 18-20%)

Medium

Q1 delivered 15.4%. One-offs ₹8.5 Cr; normalized ~18.5%. Geopolitical/commodity headwinds flagged.

₹100 Cr annual capex across Sandila & Hamirpur

High

₹70-100 Cr Hamirpur + ₹25-30 Cr Sandila. No debt; funded from cash flows. Multi-year commitment to ₹1,000 Cr Hamirpur.

Risks the call surfaced

Ranked by how much they should concern a holder

Demand cyclicality

High

Erratic rainfall delays sowing, depresses Pretilachlor (key herbicide for paddy). Q1 volume -13%. Risk: sustained erratic monsoon extends softness 2-3 quarters.

Product concentration

Medium

Pretilachlor (herbicide for paddy) is core product. Bad monsoon year → volumes collapse. No quantified percentage, but flagged in Q&A as structural vulnerability.

Execution risk

Medium

Hamirpur only 2/10 blocks live. FY27 revenue target ₹50-60 Cr (revised down from ₹70-100 Cr hope). ₹1,000 Cr target by FY30 requires flawless 3-4 year execution.

Pricing/competition

Medium

Chinese products undercutting on price. New fungicide import-replacement product (4k-5k MT market) targets ₹500-600/kg; Chinese likely lower. Margin erosion risk if capex efficiency or volumes don't scale.

Working capital

Low

Built ₹6 Cr job work charges in anticipation of Q1 demand that didn't materialize. Inventory days 200 vs 170 normal. Expected to normalize Q3 when season begins.

Management

Score 7/10. Clear, transparent. One-offs disclosed (₹2.5 Cr write-off, ₹6 Cr job work). Roadmap quantified (8-10 blocks, capex plans). Some hedging on new product upside (not naming fungicide). No major evasions. Mixed. Q1 missed prior ≥20% FY27 guidance (now single-digit). Capex on track (₹100 Cr/yr). EU approval real. New products in early stage (not yet material). Inventory build was speculative mistake.

What to watch next

1 · Sep 2026
Monsoon season picks up; herbicide demand recovery expected (Pretilachlor ramp in Q2/Q3)
2 · Nov 2026
EU TEQ approval fungicide sales commence; ₹30-40 Cr incremental revenue target from direct customers
3 · FY27 end
New fungicide product (import replacement, 4k-5k MT market) ramps at Sandila; ₹10-12 Cr revenue potential

Risk: sustained monsoon volatility or Hamirpur ramp delay could extend near-term pain.

Informational and educational content only. Not investment advice.